(Q37778400)

23 August 2017

1 reference

title

Emerging drugs for high-grade osteosarcoma (English)

1 reference

23 August 2017

Michela Pasello

2

0 references

Claudia Maria Hattinger

object named as

Claudia Maria Hattinger

1

0 references

Massimo Serra

object named as

Massimo Serra

5

0 references

Piero Picci

object named as

Piero Picci

4

0 references

author name string

Stefano Ferrari

3

1 reference

PubMed ID

20690888

23 August 2017

language of work or name

English

0 references

publication date

9 August 2010

1 reference

Expert Opinion on Emerging Drugs

23 August 2017

1 reference

23 August 2017

15

1 reference

23 August 2017

4

1 reference

23 August 2017

615-634

1 reference

Biology and therapeutic advances for pediatric osteosarcoma

23 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Chemotherapy resistance in osteosarcoma: current challenges and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

The epidemiology of osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Follow-up study of long-term survivors of osteosarcoma in the prechemotherapy era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Preoperative chemotherapy for osteogenic sarcoma:Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Patterns of care and survival for patients aged under 40 years with bone sarcoma in Britain, 1980-1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Sarcomas and pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Prognostic value of P-glycoprotein in high-grade osteosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Cisplatin: mode of cytotoxic action and molecular basis of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Targeted therapies in bone sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Redundancy of autocrine loops in human osteosarcoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Functional genome screen for therapeutic targets of osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

The role of IGF-1R in pediatric malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Novel agents in development for pediatric sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Initial testing of dasatinib by the pediatric preclinical testing program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Role of glutathione transferases in the mechanism of brostallicin activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Small-molecule cyclin-dependent kinase modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Roscovitine modulates DNA repair and senescence: implications for combination chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Physiological and oncogenic Aurora-A pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

NVP-BEZ235 as a new therapeutic option for sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

The role of mTOR in the management of solid tumors: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Phase I study of everolimus in pediatric patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Therapy for osteosarcoma: where do we go from here?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Zoledronic acid inhibits osteosarcoma growth in an orthotopic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

ABC transporters as potential targets for modulation of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

ABC transporters in cancer: more than just drug efflux pumps.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Inhibitory effect of curcumin on MDR1 gene expression in patient leukemic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

The role of interferons in the treatment of osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Novel therapeutic agents for osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

Prognostic factors and outcomes for osteosarcoma: An international collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.505603

10.1517/14728214.2010.505603

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

20690888